The influence of long-term therapy with the insulin pump (CSII) in patients with type 1 diabetes mellitus on metabolic compensation and on the incidence of hypoglycaemia. Comparison with intensified conventional insulin therapy (MDI);Vliv dlouhodobé terapie inzulinovou pumpou (CSII) u pacientů s diabetes mellitus 1. typu na metabolickou kompenzaci a výskyt hypoglykemií. Porovnání s intenzifikovanou konvenční inzulinovou terapií (MDI)

Vnitrni Lekarstvi

Volumn 53, Issue 6, 2007, Pages 637-645

  Olšovský, Jindřich ^a   Beranek M ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Average glycaemia; Diabetes compensation; Glycated haemoglobin; Hypoglycaemia; Insulin pump; Type 1 diabetes mellitus

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; METABOLISM; MORBIDITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; ADULT; BLOOD; COMPARATIVE STUDY; FEMALE; INSULIN INFUSION; MALE;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE;

EID: 34347230478     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L et al. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ 1992; 304: 19-22.
2. Mogensen CE. Management of diabetic renal involvement and disease. Lancet 1988; 1: 867-870.
3. Tattersalll RB The quest for normoglycemia: a historical perspective. Diabetologia 1994; 11: 618-635.
4. The Diabetes Control and Complications Trial research group: The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Kohner EM. The effect of diabetic control on diabetic retinopathy. Eye 1993; 7: 309-311.
6. Reichard P. Are there any glycemic thresholds for the serious microvascular diabetic complications? J Diab Compl 1995; 9: 25-30.
7. Pickup JC, Keen H, Parsons JA et al. Continuous subcutaneous insulin infusion: an aproach to achieving normoglycemia. Br Med J 1978; 1: 204-207.
8. Diabetes control and Complications Trial Research Group: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361-376.
9. Strowig SM. Initiation and management of insulin pump therapy. Diabetes Educ 1993; 19: 50-58.
10. Olšovský J. Inzulínová pumpa. In: Perušičová J. Trendy soudobé diabetologie. Praha: Galén 2004: Vol 9, 49-71.
11. Pickup J, Keen H. Continuous subcutaneous insulin infusion et 25 years. Diabetes Care 2002; 25: 593-598.
12. Jankovec Z, Čechurová D, Krčma M et al. Dlouhodobý efekt léčby inzulínovou pumpou (CSII) - výsledky registru pacientů léčených CSII v České republice DMEV 2006; Suppl 2: 26.
13. Koivisto VA, Yki-Yarvinen H, Helve E et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986; 35: 78-82.
14. Kane K, Jansenn MMU, Keulen ETP et al. Substitution of nighttime CSII therapy for bedtime NPH insulin in a multiple injection regimen improves contraregulatory hormonal response and warning symptoms of hypoglycemia in IDDM. Diabetologia 1998; 41: 322-329.
15. Carrol MF, Schade DS. The dawn fenomenon revisited: implications for diabetes therapy. Endocr Pract 2005; 11: 55-64.
16. Eichner HL, Selan JL, Hollemann CB et al. Reduction of severe hypoglycemic events in type 1 diabetic patients using continuous subcutaneous insulin infusion. Diabetes Res 1988; 8: 189-193.
17. Brož J, Kožnarová R, Bartášková D et al. Současne možnosti léčby diabetes mellitus pomocí inzulínových pump. DMEV 2006; 4: 179-186.
18. Kožnarová R. Přehled pump dostupných v ČR. Remedia 2006; 2: 188.
19. Retnakaran R, Zinman B. CSII vs. MDI: insights from a Health Technology Assessment review. International Diabetes Monitor 2006; 18: 20-22.
20. Retnakaran R, DeVries JH, Hanaire-Broutin H et al. Continuous subcutaneous insulin infusion versus multiple daily injections: modeling predicted benefits in relationship to baseline A1c. Diabetes Care 2005; 28: 1835-1836.
21. Hirsch IB, Bode BW, Garg S et al. for the Insulin Aspart CSII/MDI Comparison Study Group. Continuous subcutaneous insulin infusion of insulin aspart versus multiple daily injection of insulin aspart/ insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28: 533-538.
22. Jankovec Z, Krčma M, Lacigová S et al. Registr pacientů léčených inzulínovou pumpou v České republice. DMEV 2004; Suppl 1: 22,
23. Melki V, Renard E, Lassmann-Vague V et al. Improvement of HBA1c and blood glucose stability in IDDM patients with lispro insulin analogue in external pump. Diabetes Care 2001; 24: 69-72.
24. Renner R, Pfurzner A, Traurman M et al. Use of insulin lispro in CSII treatment. Diabetes Care 1999; 22: 784-788.
25. Schmaus S, Konig A, Landgraf R. Human insulin analogue (lispro) the ideal pump insulin? Diabet Med 1998; 15: 247-249.
26. Zinman B, Tildesley H, Chiasson J-L et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440-443.
27. Bode B, Weinstein R, Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in CSII. Diabetes Care 2002; 25: 439-444.
28. Bode B, Steed D, Davidson P. Long-term pump use and SMBG in 205 patients. Diabetes 1994; 43 (Suppl 1): 220A.
29. Bode B, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in CSII therapy with Type 1 diabetes mellitus. Diabetes Care 2001; 24: 69-72.
30. Hoogma RPLM, Schumicki D. Safety of Insulin Glulisine when Given by Continuous Subcutaneous Infusion Using an External Pump in Patients with Type 1 Diabetes. Horm Metab Res 2006; 38: 429-433.
31. McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels then glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 2006; 29: 352-355.
32. Ng Tang Pui S, Pickup J, Bending JJ. Hypoglycemia and counterregulation in insulin-dependent patients: a comparison of CSII and conventional insulin therapy. Diabetes Care 1986; 15: 221-227.
33. Ronn B, Mathiesen ER, Vang L et al. Evaluation of insulin pump treatment under routine conditions. Diabetes Res Clin Pract 1989; 3: 191-196.
34. Chantelau E, Spraul M, Muhlhauser I et al. Long term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 diabetes mellitus: a one centre experience. Diabetologia 1989; 32: 421-426.
35. Bell DSH, Cutter G, Clements RS. The feasibility of long-term treatment of diabetes with continuous subcutaneous insulin infusion. Diab Nutr Metab 1993; 6: 57-60.
36. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control. J Diabetes Complications 2005; 19: 178-181.
37. Doležal T. Farmakoekonomické aspekty léčby diabetu. Farmakoekonomika 2006; 1: 8-12.